>> Yes, Rick Harmon's question is still on my to-do list. <<
So fast! Here's some more help......
Monday December 13, 4:00 pm Eastern Time
Company Press Release
SOURCE: Incyte Pharmaceuticals, Inc.
Incyte and Oxford Gene Technology Ltd Cross
License Microarray and Gene Expression Patents
PALO ALTO, Calif., and OXFORD, United Kingdom, Dec. 13 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq:
INCY - news) and Oxford Gene Technology Ltd, announced today that they have entered into a cross licensing agreement
covering each other's microarray and gene expression technology patent portfolios. Financial terms of the agreement were not
disclosed.
Under terms of the agreement, Incyte has licensed from Oxford Gene Technology patents for inventions made by Professor
Edwin Southern of Oxford University. These pioneering patents date from 1988 and cover fundamental technologies for the
microarray and gene expression fields. The ''Southern Patents'' will be licensed to Incyte co-exclusively for the creation of large
databases of gene expression data, which are licensed to multiple parties, and non-exclusively for all other uses.
Oxford Gene Technology will obtain non-exclusive licenses from Incyte under Incyte's microarray and gene expression patent
portfolio, which includes patents and patent applications covering microarrays, methods of manufacture of microarrays, gene
expression analysis, sample preparation, and for identifying disease-associated genes using hybridization assays, which include
microarray-based analysis.
''This agreement provides Incyte co-exclusive rights to the Southern Patents for the creation of large gene expression
databases for multiple licensing,'' said Lee Bendekgey, General Counsel and Interim CFO of Incyte. ''We believe this patent
portfolio will become one of the broadest in the microarray field, and that this license will give Incyte valuable freedom to
operate as its microarray and expression programs expand and evolve. We are also pleased to be granting OGT a license to
Incyte's extensive microarray and gene expression technology patent portfolio.''
''We are delighted that this license to Incyte will widen access to array technology, especially for large-scale commercial
high-density microarray products and services,'' said Ed Southern, Chairman of OGT. ''In addition, this agreement gives OGT
access to key intellectual property from Incyte covering a broad range of technologies associated with the production and use
of microarrays.''
Oxford Gene Technology was established to exploit the microarray and related technology arising from research carried out by
Professor Southern and his team at the University of Oxford. In addition to its licensing activities, OGT has recently established
an operational arm under the leadership of Dr. Andy Millar to provide services to the pharmaceutical and other sectors in
antisense discovery, probe optimization, resequencing and expression analysis, employing techniques developed by Dr.
Southern and his team. For more information visit OGT's Web site at www.ogt.co.uk.
Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the
understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management
software, microarray-based gene expression services, related reagents and services. These products and services assist
pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery,
understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to
disease. For more information, visit Incyte's Web site at www.incyte.com.
Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements
within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a
discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Annual Report on Form 10-Q for
the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Incyte Pharmaceuticals, Inc. |
